Hainan Poly Pharm Co Ltd
SZSE:300630
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 3-Year Average (0.3), the stock would be worth ¥11.34 (1 174% upside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0 | ¥0.89 |
0%
|
| 3-Year Average | 0.3 | ¥11.34 |
+1 174%
|
| 5-Year Average | 0.5 | ¥20.09 |
+2 157%
|
| Industry Average | 2.4 | ¥87.91 |
+9 777%
|
| Country Average | 2.4 | ¥89.47 |
+9 953%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
H
|
Hainan Poly Pharm Co Ltd
SZSE:300630
|
68.4m CNY | 0 | -5.5 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
883B USD | 33.3 | 42.8 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
553.5B USD | 6.8 | 26.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 7.7 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.3B GBP | 6.1 | 27.6 | |
| CH |
|
Novartis AG
SIX:NOVN
|
221.1B CHF | 7.3 | 20.7 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
270.2B USD | 5.1 | 14.8 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | -58.7 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 6.3 | 12 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.8B USD | 1.8 | 19.5 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
122B USD | 6.6 | 17.3 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.5 |
| Median | 2.4 |
| 70th Percentile | 3.9 |
| Max | 1 172 445.9 |
Other Multiples
Hainan Poly Pharm Co Ltd
Glance View
Hainan Poly Pharm.Co., Ltd. engages in the manufacture and sale of pharmaceutical products. The company is headquartered in Haikou, Hainan and currently employs 1,221 full-time employees. The company went IPO on 2017-03-28. The firm operates five segments. The Anti-Allergic segment is engaged in the production of desloratadine dispersible tablets, desloratadine dry suspension and desloratadine tablets. The Antibiotic segment provides levofloxacin hydrochloride capsules and azithromycin dry suspension for the treatment of bacterial infections. The Nonsteroidal Anti-inflammatory Drugs segment provides diclofenac sodium enteric-coated sustained-release capsule products for the treatment of arthritis and dysmenorrhea. The Digestive segment is involved in providing trimebutine maleate tablets to treat abdominal pain, diarrhea, and irritable bowel syndrome. The firm also operates Other segment.
